Literature DB >> 30141348

Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.

Vincenzo Di Nunno1, Alessia Cimadamore2, Matteo Santoni3, Marina Scarpelli2, Michelangelo Fiorentino4, Chiara Ciccarese5, Roberto Iacovelli5, Liang Cheng6, Antonio Lopez-Beltran7, Francesco Massari1, Rodolfo Montironi2.   

Abstract

Entities:  

Keywords:  MET inhibitor; bone metastasis; cabozantinib; castration-resistant prostate cancer; metastatic RCC; multityrosine kinases inhibitor; osteoblastic activation; renal cell carcinoma; target therapy;  angiogenesis

Mesh:

Substances:

Year:  2018        PMID: 30141348     DOI: 10.2217/fon-2018-0158

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  2 in total

1.  Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma.

Authors:  Vincenzo Di Nunno; Francesco Massari; Veronica Mollica; Alessia Cimadamore; Matteo Santoni; Liang Cheng; Antonio Lopez-Beltran; Marina Scarpelli; Rodolfo Montironi
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Bone Metastasis: Current State of Play.

Authors:  Anthony Turpin; Martine Duterque-Coquillaud; Marie-Hélène Vieillard
Journal:  Transl Oncol       Date:  2019-12-23       Impact factor: 4.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.